| Sebastian O Hubbuch, MD | |
|
2300 Manchester Expy, Ste 1003, Columbus, GA 31904-6877 | |
| (706) 565-7382 | |
| (706) 565-9110 |
| Full Name | Sebastian O Hubbuch |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 43 Years |
| Location | 2300 Manchester Expy, Columbus, Georgia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1811994403 | NPI | - | NPPES |
| 142202 | Medicaid | AL | |
| 000390684J | Medicaid | GA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 23990 (Georgia) | Secondary |
| 207RI0011X | Internal Medicine - Interventional Cardiology | 023990 (Georgia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Piedmont Walton Hospital | Monroe, GA | Hospital |
| Piedmont Newton Hospital | Covington, GA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Piedmont Cardiology Of Atlanta, Llc | 0345321691 | 402 |
News Archive
A new drug derived from magnolia trees appears to be able to uncouple two important functions of thrombin in blood clot formation and may offer a way to better control the potentially dangerous complications of bleeding and clot formation during procedures to open blocked coronary arteries, say researchers at the Duke Clinical Research Institute (DCRI).
The University of Nottingham spin-out company, Oncimmune Ltd, has developed a ground breaking blood test which will aid the detection of cancer as much as five years earlier than current testing methods such as mammography and CT scans. Physicians will know the result of their patient's test within one week of sending in a blood sample to Oncimmune.
For more than a decade, there have been no new therapies that have improved survival rates for patients with advanced melanoma. Today, at the 6th International Melanoma Congress for the Society for Melanoma Research, the Melanoma Research Foundation (MRF) announced a novel collaboration between the research community and pharmaceutical companies that will pool knowledge and resources to generate new breakthroughs in treatment.
RNA is becoming an interesting drug target as it takes possible intervention back one step to the synthesis of a target protein, instead of trying to block or inhibit a process.
Researchers analyzed data on three variants of concern and found that viral loads were higher and infection lasted longer for the B.1.1.7 variant. They all were more infectious than the original strain, and transmissibility also depended on population demographics.
› Verified 4 days ago
| Entity Name | Columbus Ambulatory Healthcare Services, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790733244 PECOS PAC ID: 1355244385 Enrollment ID: O20040128000790 |
News Archive
A new drug derived from magnolia trees appears to be able to uncouple two important functions of thrombin in blood clot formation and may offer a way to better control the potentially dangerous complications of bleeding and clot formation during procedures to open blocked coronary arteries, say researchers at the Duke Clinical Research Institute (DCRI).
The University of Nottingham spin-out company, Oncimmune Ltd, has developed a ground breaking blood test which will aid the detection of cancer as much as five years earlier than current testing methods such as mammography and CT scans. Physicians will know the result of their patient's test within one week of sending in a blood sample to Oncimmune.
For more than a decade, there have been no new therapies that have improved survival rates for patients with advanced melanoma. Today, at the 6th International Melanoma Congress for the Society for Melanoma Research, the Melanoma Research Foundation (MRF) announced a novel collaboration between the research community and pharmaceutical companies that will pool knowledge and resources to generate new breakthroughs in treatment.
RNA is becoming an interesting drug target as it takes possible intervention back one step to the synthesis of a target protein, instead of trying to block or inhibit a process.
Researchers analyzed data on three variants of concern and found that viral loads were higher and infection lasted longer for the B.1.1.7 variant. They all were more infectious than the original strain, and transmissibility also depended on population demographics.
› Verified 4 days ago
| Entity Name | Chhokar Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619079100 PECOS PAC ID: 6800883463 Enrollment ID: O20040427000953 |
News Archive
A new drug derived from magnolia trees appears to be able to uncouple two important functions of thrombin in blood clot formation and may offer a way to better control the potentially dangerous complications of bleeding and clot formation during procedures to open blocked coronary arteries, say researchers at the Duke Clinical Research Institute (DCRI).
The University of Nottingham spin-out company, Oncimmune Ltd, has developed a ground breaking blood test which will aid the detection of cancer as much as five years earlier than current testing methods such as mammography and CT scans. Physicians will know the result of their patient's test within one week of sending in a blood sample to Oncimmune.
For more than a decade, there have been no new therapies that have improved survival rates for patients with advanced melanoma. Today, at the 6th International Melanoma Congress for the Society for Melanoma Research, the Melanoma Research Foundation (MRF) announced a novel collaboration between the research community and pharmaceutical companies that will pool knowledge and resources to generate new breakthroughs in treatment.
RNA is becoming an interesting drug target as it takes possible intervention back one step to the synthesis of a target protein, instead of trying to block or inhibit a process.
Researchers analyzed data on three variants of concern and found that viral loads were higher and infection lasted longer for the B.1.1.7 variant. They all were more infectious than the original strain, and transmissibility also depended on population demographics.
› Verified 4 days ago
| Entity Name | Columbus Diagnostic Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1316108624 PECOS PAC ID: 3375455884 Enrollment ID: O20040429001218 |
News Archive
A new drug derived from magnolia trees appears to be able to uncouple two important functions of thrombin in blood clot formation and may offer a way to better control the potentially dangerous complications of bleeding and clot formation during procedures to open blocked coronary arteries, say researchers at the Duke Clinical Research Institute (DCRI).
The University of Nottingham spin-out company, Oncimmune Ltd, has developed a ground breaking blood test which will aid the detection of cancer as much as five years earlier than current testing methods such as mammography and CT scans. Physicians will know the result of their patient's test within one week of sending in a blood sample to Oncimmune.
For more than a decade, there have been no new therapies that have improved survival rates for patients with advanced melanoma. Today, at the 6th International Melanoma Congress for the Society for Melanoma Research, the Melanoma Research Foundation (MRF) announced a novel collaboration between the research community and pharmaceutical companies that will pool knowledge and resources to generate new breakthroughs in treatment.
RNA is becoming an interesting drug target as it takes possible intervention back one step to the synthesis of a target protein, instead of trying to block or inhibit a process.
Researchers analyzed data on three variants of concern and found that viral loads were higher and infection lasted longer for the B.1.1.7 variant. They all were more infectious than the original strain, and transmissibility also depended on population demographics.
› Verified 4 days ago
| Entity Name | Piedmont Cardiology Of Atlanta, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275729691 PECOS PAC ID: 0345321691 Enrollment ID: O20080114000153 |
News Archive
A new drug derived from magnolia trees appears to be able to uncouple two important functions of thrombin in blood clot formation and may offer a way to better control the potentially dangerous complications of bleeding and clot formation during procedures to open blocked coronary arteries, say researchers at the Duke Clinical Research Institute (DCRI).
The University of Nottingham spin-out company, Oncimmune Ltd, has developed a ground breaking blood test which will aid the detection of cancer as much as five years earlier than current testing methods such as mammography and CT scans. Physicians will know the result of their patient's test within one week of sending in a blood sample to Oncimmune.
For more than a decade, there have been no new therapies that have improved survival rates for patients with advanced melanoma. Today, at the 6th International Melanoma Congress for the Society for Melanoma Research, the Melanoma Research Foundation (MRF) announced a novel collaboration between the research community and pharmaceutical companies that will pool knowledge and resources to generate new breakthroughs in treatment.
RNA is becoming an interesting drug target as it takes possible intervention back one step to the synthesis of a target protein, instead of trying to block or inhibit a process.
Researchers analyzed data on three variants of concern and found that viral loads were higher and infection lasted longer for the B.1.1.7 variant. They all were more infectious than the original strain, and transmissibility also depended on population demographics.
› Verified 4 days ago
| Entity Name | St Francis Physician Practices Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326749417 PECOS PAC ID: 8729381033 Enrollment ID: O20160120002073 |
News Archive
A new drug derived from magnolia trees appears to be able to uncouple two important functions of thrombin in blood clot formation and may offer a way to better control the potentially dangerous complications of bleeding and clot formation during procedures to open blocked coronary arteries, say researchers at the Duke Clinical Research Institute (DCRI).
The University of Nottingham spin-out company, Oncimmune Ltd, has developed a ground breaking blood test which will aid the detection of cancer as much as five years earlier than current testing methods such as mammography and CT scans. Physicians will know the result of their patient's test within one week of sending in a blood sample to Oncimmune.
For more than a decade, there have been no new therapies that have improved survival rates for patients with advanced melanoma. Today, at the 6th International Melanoma Congress for the Society for Melanoma Research, the Melanoma Research Foundation (MRF) announced a novel collaboration between the research community and pharmaceutical companies that will pool knowledge and resources to generate new breakthroughs in treatment.
RNA is becoming an interesting drug target as it takes possible intervention back one step to the synthesis of a target protein, instead of trying to block or inhibit a process.
Researchers analyzed data on three variants of concern and found that viral loads were higher and infection lasted longer for the B.1.1.7 variant. They all were more infectious than the original strain, and transmissibility also depended on population demographics.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sebastian O Hubbuch, MD Po Box 9265, Columbus, GA 31908-9265 Ph: (706) 565-7382 | Sebastian O Hubbuch, MD 2300 Manchester Expy, Ste 1003, Columbus, GA 31904-6877 Ph: (706) 565-7382 |
News Archive
A new drug derived from magnolia trees appears to be able to uncouple two important functions of thrombin in blood clot formation and may offer a way to better control the potentially dangerous complications of bleeding and clot formation during procedures to open blocked coronary arteries, say researchers at the Duke Clinical Research Institute (DCRI).
The University of Nottingham spin-out company, Oncimmune Ltd, has developed a ground breaking blood test which will aid the detection of cancer as much as five years earlier than current testing methods such as mammography and CT scans. Physicians will know the result of their patient's test within one week of sending in a blood sample to Oncimmune.
For more than a decade, there have been no new therapies that have improved survival rates for patients with advanced melanoma. Today, at the 6th International Melanoma Congress for the Society for Melanoma Research, the Melanoma Research Foundation (MRF) announced a novel collaboration between the research community and pharmaceutical companies that will pool knowledge and resources to generate new breakthroughs in treatment.
RNA is becoming an interesting drug target as it takes possible intervention back one step to the synthesis of a target protein, instead of trying to block or inhibit a process.
Researchers analyzed data on three variants of concern and found that viral loads were higher and infection lasted longer for the B.1.1.7 variant. They all were more infectious than the original strain, and transmissibility also depended on population demographics.
› Verified 4 days ago
Andrew N Vernon, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2122 Manchester Expy, Columbus, GA 31904 Phone: 706-320-2773 Fax: 706-596-4226 | |
Dr. Christopher Morgan Lee, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 700 Center St, Suite 204, Columbus, GA 31901 Phone: 706-596-1314 Fax: 706-596-9225 | |
Dr. James Lacey Smith, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 1207 Marina Cove Dr, Columbus, GA 31904 Phone: 901-412-1881 | |
Srividya Srinivasamaharaj, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1831 5th Ave, Columbus, GA 31904 Phone: 706-320-8780 Fax: 706-320-8721 | |
Dr. Mylena E Morton, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 710 Center St, Columbus, GA 31901 Phone: 706-571-1262 Fax: 706-660-6512 | |
Da Monica Alethea Cannon, NP Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2737 Warm Springs Rd Ste C, Columbus, GA 31904 Phone: 706-571-1136 | |
Dr. Gregory Michael Rucker, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 700 Center St, Suite 204, Columbus, GA 31901 Phone: 706-596-1314 Fax: 706-596-9225 |